Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the m
Slide 3: Overview of Meridian Bioscience, Inc.
Overview of Meridian Bioscience, Inc. Leading developer, manufacturer and distributor of innovative rapid tests for diagnosing common diseases Preferred OEM supplier of critical components to large, automated Dx test manufacturers Products sold in over 60 countries US Dx 67% VIVO
Slide 4: Overview of Meridian Bioscience, Inc. - Our Focus
Overview of Meridian Bioscience, Inc. Our Focus VIVO Upper Respiratory HAI (C. difficile) Biologicals to Dx industry Foodborne Stomach Ulcers (H. pylori)
Slide 5: Strong, consistent financial leverage
Overview of Meridian Bioscience Strong, consistent financial leverage 5 year CAGR (2009) Sales 13% EPS 24% 5 year trends (2005-2009) GP +400 bps to 63% Operating income margin +1100 bps to 33% Net income +800 bps to 22% Sales per employee $351,000, up 47% Robust dividend policy - 19 years 75-85% of
Slide 6: Goal for New Product Development
Goal for New Product Development Acute symptoms Cough/cold Gastritis Diarrhea "Treatable" infection VIVO "Test and Treat" Better patient care Lower costs of healthcare
Slide 7: 2010 Trends (excluding illumigene)
2010 Trends (excluding illumigene(tm)) VIVO
Slide 8: Update: 2010 Public Financial Guidance
Update: 2010 Public Financial Guidance Net Sales $145 to $153 million Diluted EPS $0.70 to $0.80 Net Income -13% to Flat VIVO * Excludes the impact of illumigene or any other new products or acquisitions
Slide 9: Balance Sheet Summary
Balance Sheet Summary ($ in 000s except per share data) 12/31/09 12/31/08 Cash and Investments $67,730 $57,982 Long Term Debt $ - 0 - $ - 0 - Shareholders' Equity $140,426 $131,427 Total Assets $154,723 $146,125 VIVO
Slide 10: C. difficile Assay Protocol
C. difficile Assay Protocol 2 3 4 No sophisticated equipment required C. difficile test submitted for FDA 510k clearance VIVO Not yet cleared by the FDA
Slide 11: C. difficile Timeline (Preliminary)
C. difficile Timeline (Preliminary) FEBRUARY MARCH APRIL MAY JUNE JULY AUGUST Clinical Trials Complete Available for Sale Ex - U.S. FDA 510k Submission Clinical Virology Symposium American Society Microbiology American Association for Clinical Chemistry *Available For Sale U.S. *Not yet cleared by t
Slide 12: Comparison to Cytotoxic Culture
Comparison to Cytotoxic Culture Culture illumigene C. difficile illumigene C. difficile illumigene C. difficile illumigene C. difficile Positive Negative Invalid Total Positive 99 5 4 108 Negative 27 546 16 589 Total 126 551 20 697 95% CI 95% CI Sensitivity 99/104 95.2% 89.2 -97.9% 89.2 -97.9% Speci